BioMarin Pharmaceutical (BMRN) AI Stock Analysis

• Market Cap: $11.44B
• Dividend Yield: N/A
• Average Volume (3M): 1.87M
• Price to Earnings (P/E): 22.1
• Beta (1Y): 0.44
• Revenue Growth: 17.99%
• EPS Growth: 152.10%
• Country: US
• Employees: 3,040
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): 0.95
• Shares Outstanding: 191,775,670
• 10 Day Avg. Volume: 1,362,927
• 30 Day Avg. Volume: 1,874,967
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.16
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 5.82
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $97.37
• Price Target Upside: 62.77% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 21

BioMarin Pharmaceutical is well-positioned with strong financial performance, highlighted by robust revenue and profit growth, and a solid balance sheet. Technical analysis suggests caution with bearish indicators, but valuation remains reasonable given growth expectations. The positive sentiment from the earnings call supports the company's strategic positioning and operational strength. Challenges include managing VOXZOGO's revenue dynamics and tariff exposure, but overall, the outlook remains optimistic.

Positive Factors

Drug Development

The Phase III PEGASUS trial of Palynziq in adolescents with phenylketonuria met its primary endpoint, demonstrating a significant lowering in blood Phe levels compared to diet alone.

Earnings

BioMarin's first quarter revenue of $745 million, a year-over-year increase of 15%, beat both the estimate of $735.6 million and consensus of $738.1 million.

Sales Growth

Voxzogo's growth continues to be strong with a 40% year-over-year increase.

Negative Factors

Market Competition

Emerging therapies with competitive risk/benefit profiles, such as PTC’s sepiapterin, could pose a competitive threat to Palynziq in the market.

Revenue Variability

There was a modest quarter-over-quarter revenue decline due to the complexity of market dynamics and the variability of ex-U.S. government orders.

Safety Concerns

There is uncertainty about safety results due to the existing black-box warning for Palynziq, which could affect investor perception.

BioMarin Pharmaceutical Business Overview & Revenue Model

Company Description

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

How the Company Makes Money

BioMarin Pharmaceutical generates revenue through the development, production, and sales of its pharmaceutical products. The company's primary revenue streams come from the commercial sales of its approved therapies, such as Kuvan and Palynziq for PKU and Vimizim for MPS IV. BioMarin also earns money through collaborations and licensing agreements with other pharmaceutical companies, leveraging its proprietary research and development capabilities. Additionally, the company may receive milestone payments and royalties from partnered products. Key factors contributing to its earnings include successful product launches, regulatory approvals, and the expansion of its product pipeline addressing rare and underserved medical conditions.

BioMarin Pharmaceutical Financial Statement Overview

Summary

BioMarin Pharmaceutical demonstrates strong financial performance with significant revenue and profit growth. The company's income statement shows robust revenue growth from $2.09 billion in 2022 to $2.93 billion TTM, with improved profit margins. The balance sheet is solid with low leverage, and cash flow management is commendable with strong free cash flow growth. These factors enhance the company's financial stability and operational efficiency.

Income Statement

BioMarin Pharmaceutical has demonstrated a robust financial performance with strong revenue growth, rising from $2.09 billion in 2022 to $2.93 billion TTM (Trailing-Twelve-Months). The gross profit margin remains healthy, supported by efficient cost management. The net profit margin and EBIT margins have also shown significant improvement, indicating enhanced profitability. The consistent EBITDA margin growth highlights operational efficiency gains.

Balance Sheet

The company's balance sheet is strong, characterized by a low debt-to-equity ratio, suggesting prudent financial leverage. The equity ratio is impressive, indicating a high level of asset financing through equity. The return on equity has improved substantially, showcasing the company's ability to generate profits from shareholders' investments. However, the company should continue monitoring its debt levels to maintain financial flexibility.

Cash Flow

BioMarin Pharmaceutical has demonstrated strong cash flow dynamics with significant growth in free cash flow, reflecting effective capital expenditure management. The operating cash flow to net income ratio is favorable, indicating robust cash generation capabilities. The improved free cash flow to net income ratio further underscores the company's solid cash flow management.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.85B	2.42B	2.10B	1.85B	1.86B
	Gross Profit
2.27B	1.84B	1.61B	1.38B	1.34B
	EBIT
484.21M	194.44M	57.55M	-60.01M	-96.26M
	EBITDA
650.86M	310.28M	267.51M	48.03M	-5.85M
	Net Income Common Stockholders
426.86M	167.65M	141.56M	-64.08M	854.03M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.14B	1.07B	1.29B	1.01B	1.07B
	Total Assets
6.99B	6.84B	6.38B	6.00B	5.85B
	Total Debt
602.71M	1.10B	1.08B	1.08B	1.08B
	Net Debt
-340.13M	340.62M	358.49M	491.80M	425.99M
	Total Liabilities
1.33B	1.89B	1.77B	1.73B	1.74B
	Stockholders Equity
5.66B	4.95B	4.60B	4.27B	4.11B
Cash Flow		Free Cash Flow
475.42M	51.65M	44.36M	185.31M	-52.15M
	Operating Cash Flow
572.84M	159.26M	175.90M	304.54M	85.36M
	Investing Cash Flow
136.49M	-111.24M	-20.03M	-366.31M	-53.62M
	Financing Cash Flow
-526.45M	-18.73M	-18.65M	-48.00K	181.12M

BioMarin Pharmaceutical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 59.82
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMRN, the sentiment is Negative. The current price of 59.82 is below the 20-day moving average (MA) of 60.72, below the 50-day MA of 65.79, and below the 200-day MA of 70.37, indicating a bearish trend. The MACD of -1.12 indicates Negative momentum. The RSI at 40.34 is Neutral, neither overbought nor oversold. The STOCH value of 9.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BMRN.

BioMarin Pharmaceutical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GMAB	81 Outperform	$13.02B	11.54	23.16%	―	30.43%	82.29%
EXEL	80 Outperform	$10.16B	20.80	23.13%	―	18.49%	176.71%
UTHR	78 Outperform	$13.31B	11.77	19.94%	―	19.85%	21.16%
BMRN	77 Outperform	$11.44B	22.13	9.64%	―	17.99%	152.10%
INCY	75 Outperform	$11.54B	184.44	0.47%	―	17.13%	-88.78%
ASND	52 Neutral	$9.83B	―	357.68%	―	10.69%	34.71%
Sector *	52 Neutral	$5.23B	3.70	-41.86%	2.84%	16.58%	-0.16%

BioMarin Pharmaceutical Corporate Events

BioMarin Expands Board with New Independent Director

On February 20, 2025, BioMarin Pharmaceutical’s Board of Directors expanded from eleven to twelve members, appointing Timothy P. Walbert as an independent director effective February 24, 2025. Mr. Walbert will receive standard director fees and a pro rata share of the 2024 annual award of $400,000 in restricted stock units, with shares vesting before the next annual meeting of stockholders. This appointment does not result from any arrangement or related party transaction.